Literature DB >> 25452562

Ex vivo-expanded but not in vitro-induced human regulatory T cells are candidates for cell therapy in autoimmune diseases thanks to stable demethylation of the FOXP3 regulatory T cell-specific demethylated region.

Maura Rossetti1, Roberto Spreafico2, Suzan Saidin3, Camillus Chua3, Maryam Moshref4, Jing Yao Leong3, York Kiat Tan5, Julian Thumboo5, Jorg van Loosdregt4, Salvatore Albani6.   

Abstract

Regulatory T cell (Treg) therapy is a promising approach for transplant rejection and severe autoimmunity. Unfortunately, clinically meaningful Treg numbers can be obtained only upon in vitro culture. Functional stability of human expanded (e)Tregs and induced (i)Tregs has not been thoroughly addressed for all proposed protocols, hindering clinical translation. We undertook a systematic comparison of eTregs and iTregs to recommend the most suitable for clinical implementation, and then tested their effectiveness and feasibility in rheumatoid arthritis (RA). Regardless of the treatment, iTregs acquired suppressive function and FOXP3 expression, but lost them upon secondary restimulation in the absence of differentiation factors, which mimics in vivo reactivation. In contrast, eTregs expanded in the presence of rapamycin (rapa) retained their regulatory properties and FOXP3 demethylation upon restimulation with no stabilizing agent. FOXP3 demethylation predicted Treg functional stability upon secondary TCR engagement. Rapa eTregs suppressed conventional T cell proliferation via both surface (CTLA-4) and secreted (IL-10, TGF-β, and IL-35) mediators, similarly to ex vivo Tregs. Importantly, Treg expansion with rapa from RA patients produced functionally stable Tregs with yields comparable to healthy donors. Moreover, rapa eTregs from RA patients were resistant to suppression reversal by the proinflammatory cytokine TNF-α, and were more efficient in suppressing synovial conventional T cell proliferation compared with their ex vivo counterparts, suggesting that rapa improves both Treg function and stability. In conclusion, our data indicate Treg expansion with rapa as the protocol of choice for clinical application in rheumatological settings, with assessment of FOXP3 demethylation as a necessary quality control step.
Copyright © 2014 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25452562      PMCID: PMC4383769          DOI: 10.4049/jimmunol.1401145

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  56 in total

1.  Polyclonal expansion of human CD4(+)CD25(+) regulatory T cells.

Authors:  Petra Hoffmann; Ruediger Eder; Matthias Edinger
Journal:  Methods Mol Biol       Date:  2011

Review 2.  Mechanisms of impaired regulation by CD4(+)CD25(+)FOXP3(+) regulatory T cells in human autoimmune diseases.

Authors:  Jane Hoyt Buckner
Journal:  Nat Rev Immunol       Date:  2010-12       Impact factor: 53.106

3.  Enhancement of antigen-specific Treg vaccination in vivo.

Authors:  Carolin Daniel; Kerstin Wennhold; Hye-Jung Kim; Harald von Boehmer
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-30       Impact factor: 11.205

4.  Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics.

Authors:  Claudio G Brunstein; Jeffrey S Miller; Qing Cao; David H McKenna; Keli L Hippen; Julie Curtsinger; Todd Defor; Bruce L Levine; Carl H June; Pablo Rubinstein; Philip B McGlave; Bruce R Blazar; John E Wagner
Journal:  Blood       Date:  2010-10-15       Impact factor: 22.113

5.  Methylation matters: binding of Ets-1 to the demethylated Foxp3 gene contributes to the stabilization of Foxp3 expression in regulatory T cells.

Authors:  Julia K Polansky; Lisa Schreiber; Christoph Thelemann; Leif Ludwig; Melanie Krüger; Ria Baumgrass; Sascha Cording; Stefan Floess; Alf Hamann; Jochen Huehn
Journal:  J Mol Med (Berl)       Date:  2010-06-24       Impact factor: 4.599

6.  Natural naive CD4+CD25+CD127low regulatory T cell (Treg) development and function are disturbed in multiple sclerosis patients: recovery of memory Treg homeostasis during disease progression.

Authors:  Koen Venken; Niels Hellings; Tom Broekmans; Karen Hensen; Jean-Luc Rummens; Piet Stinissen
Journal:  J Immunol       Date:  2008-05-01       Impact factor: 5.422

7.  Comparison of stable human Treg and Th clones by transcriptional profiling.

Authors:  Julie Stockis; Wolfram Fink; Violaine François; Thierry Connerotte; Charles de Smet; Laurent Knoops; Pierre van der Bruggen; Thierry Boon; Pierre G Coulie; Sophie Lucas
Journal:  Eur J Immunol       Date:  2009-03       Impact factor: 5.532

8.  Increased frequency of regulatory T cells and selection of highly potent CD62L+ cells during treatment of human lung transplant recipients with rapamycin.

Authors:  Christian M Lange; Thuy Yen Vy Tran; Harald Farnik; Sven Jungblut; Torsten Born; Thomas O Wagner; Tim O Hirche
Journal:  Transpl Int       Date:  2009-10-05       Impact factor: 3.782

9.  Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor.

Authors:  Makoto Miyara; Yumiko Yoshioka; Akihiko Kitoh; Tomoko Shima; Kajsa Wing; Akira Niwa; Christophe Parizot; Cécile Taflin; Toshio Heike; Dominique Valeyre; Alexis Mathian; Tatsutoshi Nakahata; Tomoyuki Yamaguchi; Takashi Nomura; Masahiro Ono; Zahir Amoura; Guy Gorochov; Shimon Sakaguchi
Journal:  Immunity       Date:  2009-05-21       Impact factor: 31.745

10.  Role of conserved non-coding DNA elements in the Foxp3 gene in regulatory T-cell fate.

Authors:  Ye Zheng; Steven Josefowicz; Ashutosh Chaudhry; Xiao P Peng; Katherine Forbush; Alexander Y Rudensky
Journal:  Nature       Date:  2010-01-13       Impact factor: 49.962

View more
  38 in total

Review 1.  Treg cells in autoimmunity: from identification to Treg-based therapies.

Authors:  Lisa Göschl; Clemens Scheinecker; Michael Bonelli
Journal:  Semin Immunopathol       Date:  2019-04-05       Impact factor: 9.623

2.  T regulatory cell mediated immunotherapy for solid organ transplantation: A clinical perspective.

Authors:  Mohammad Afzal Khan
Journal:  Mol Med       Date:  2016-11-22       Impact factor: 6.354

Review 3.  Crosstalk between metabolism and epigenetic modifications in autoimmune diseases: a comprehensive overview.

Authors:  Zijun Wang; Hai Long; Christopher Chang; Ming Zhao; Qianjin Lu
Journal:  Cell Mol Life Sci       Date:  2018-07-04       Impact factor: 9.261

Review 4.  Regulatory T Cell Plasticity and Stability and Autoimmune Diseases.

Authors:  Runze Qiu; Liyu Zhou; Yuanjing Ma; Lingling Zhou; Tao Liang; Le Shi; Jun Long; Dongping Yuan
Journal:  Clin Rev Allergy Immunol       Date:  2020-02       Impact factor: 8.667

5.  Directed differentiation of regulatory T cells from naive T cells and prevention of their inflammation-mediated instability using small molecules.

Authors:  M-H Haddadi; B Negahdari; E Hajizadeh-Saffar; M Khosravi-Maharlooei; M Basiri; H Dabiri; H Baharvand
Journal:  Clin Exp Immunol       Date:  2020-06-08       Impact factor: 4.330

6.  Regulatory T Cell Therapy for Ischemic Stroke: how far from Clinical Translation?

Authors:  Yuguo Xia; Wei Cai; Angus W Thomson; Xiaoming Hu
Journal:  Transl Stroke Res       Date:  2016-06-16       Impact factor: 6.829

Review 7.  Functional Defects of Treg Cells: New Targets in Rheumatic Diseases, Including Ankylosing Spondylitis.

Authors:  Jinlin Miao; Ping Zhu
Journal:  Curr Rheumatol Rep       Date:  2018-04-16       Impact factor: 4.592

Review 8.  Cell Therapy in Kidney Transplantation: Focus on Regulatory T Cells.

Authors:  Nicholas A Zwang; Joseph R Leventhal
Journal:  J Am Soc Nephrol       Date:  2017-05-02       Impact factor: 10.121

Review 9.  T Follicular Regulatory Cells and Antibody Responses in Transplantation.

Authors:  Elizabeth F Wallin
Journal:  Transplantation       Date:  2018-10       Impact factor: 4.939

Review 10.  Epigenetic Variability of CD4+CD25+ Tregs Contributes to the Pathogenesis of Autoimmune Diseases.

Authors:  Ye Shu; Qinghua Hu; Hai Long; Christopher Chang; Qianjin Lu; Rong Xiao
Journal:  Clin Rev Allergy Immunol       Date:  2017-04       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.